Introduction A contribution of genetic factors to the development of stress urinary incontinence (SUI) is broadly acknowledged. This study aimed to: (1) provide insight into the genetic pathogenesis of SUI by gathering and synthesizing the available data from studies evaluating differential gene expression in SUI patients and (2) identify possible novel therapeutic targets and leads. Methods A systematic literature search was conducted through September 2017 for the concepts of genetics and SUI. Gene networking connections and gene-set functional analyses of the identified genes as differentially expressed in SUI were performed using GeneMANIA software. Results Of 3019 studies, 4 were included in the final analysis. A total of 13 genes were identified as being differentially expressed in SUI patients. Eleven genes were overexpressed: skin-derived antileukoproteinase (SKALP/elafin), collagen type XVII alpha 1 chain (COL17A1), plakophilin 1 (PKP1), keratin 16 (KRT16), decorin (DCN), biglycan (BGN), protein bicaudal D homolog 2 (BICD2), growth factor receptor-bound protein 2 (GRB2), signal transducer and activator of transcription 3 (STAT3), apolipoprotein E (APOE), and Golgi SNAP receptor complex member 1 (GOSR1), while two genes were underexpressed: fibromodulin (FMOD) and glucocerebrosidase (GBA). GeneMANIA revealed that these genes are involved in intermediate filament cytoskeleton and extracellular matrix organization. Conclusion Many genes are involved in the pathogenesis of SUI. Furthermore, whole-genome studies are warranted to identify these genetic connections. This study lays the groundwork for future research and the development of novel therapies and SUI biomarkers in clinical practice.
Introduction
Stress urinary incontinence (SUI) is a common medical problem, affecting up to 40% of adult women, that negatively impacts their social, psychologic, and hygienic well-being and quality of life [1] [2] [3] . The pathophysiology of SUI is presumably multifactorial. Many SUI risk factors are related to the pelvic floor musculature or connective tissue weakness [4] . The incidence of SUI significantly increases after menopause, particularly in women with coexisting risk factors, such as spontaneous and operative vaginal deliveries, multiparty, obesity, and metabolic syndrome [5] . In addition, SUI has been found to be closely related to coexisting pelvic organ prolapse (POP), particularly the anatomic site of the pelvic floor defect and the severity of POP [6] .
Epidemiologic studies have found that women with urinary incontinence were more likely to have family members with incontinence [7] , thus suggesting a hereditable predisposition to SUI. In fact, several studies have demonstrated that genomic factors account for as much as 40% of the total variance in SUI and POP [8] . Although the contribution of genetic factors in the development of SUI is widely accepted [9] , it has not been studied in depth. Identification of SUI-linked genes may lead to innovative diagnostic markers and novel molecular treatments. The objective of this review was to summarize the current evidence from studies evaluating gene expression levels associated with SUI and identify possible gene interactions and functional pathways, with the goal to elucidate potential therapeutic targets and clinical leads.
Methods
A systematic literature review was carried out to identify publications investigating the genetic contribution to the development of SUI relative to continent women. The search was performed in compliance with the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines for systematic review [10] . The study was registered by the International Prospective Register of Systematic Reviews (PROSPERO) under CRD42018081971.
Literature search
A systematic search strategy was developed by an expert librarian (M.N) to identify publications that studied the role of genetics in the occurrence of SUI. The search was conducted using the Ovid MEDLINE (segment: epub ahead of print, inprocess and other non-indexed citations, Ovid MEDLINE daily and Ovid MEDLINE, 1946 to present), PubMed, Elsevier Embase, Web of Science (SCI-EXPANDED), and Wiley Cochrane Central Register of Controlled Trials. Search results were limited to those published between January 1, 1990, and September 30, 2017. The search was performed using MeSH terms and Text Words such as stress urinary incontinence, genetic, gene, and gene expression. Two researchers (I.I. and A.M.) have reviewed the generated library to identify the relevant studies that contributed to this review. The detailed search strategies are available (Appendix Table 4 ).
Eligibility criteria and study selection
Only English language publications were included for screening. Inclusion criteria were gene expression analysis of SUI women compared with continent women or experimental studies on samples from human tissue. Studies were included if gene expression was detected and quantified using molecular techniques of polymerase chain reaction (PCR), immunohistochemistry (IHC), immunofluorescence staining (IF), and Western blot. In vitro gene expression studies were excluded. The genes were evaluated in pure SUI [11] , and patients with POP ≥ stage III were excluded. In addition, studies of women with prior pelvic surgery, endometriosis, or gynecologic malignant patients and those with connective tissue disorders were excluded. All manuscript titles were screened for relevancy, and all eligible manuscripts were subjected to a fulltext analysis. Figure 1 depicts the overall manuscript selection strategy and flow diagram.
Quality evaluation of the included studies
The included studies were evaluated using the Ottawa-Newcastle Quality Assessment Scale for cohort studies (Table 1) [12] . A second evaluation using the quality assessment tool from the National Heart, Lung and Blood Institute was performed ( Table 2) [13] . Overall, the included studies had average to excellent quality.
Data abstraction and analysis
A standardized form was used including study features such as reference, year of publication, country, and study design and sample type. Primary outcomes were recorded by analyzing gene expression and analysis type. The most significant genes were selected using the multiple confirmatory analyses in the selected studies. In this study, genes were selected and considered to be related to SUI if their expression was consistently validated across all the statistical and analytical methods (Western blot, RT-PCR, microarray, etc.) used in the included studies. In addition to primary outcomes, GeneMANIA, a userfriendly real-time multiple association network integration algorithm, was applied to generate gene set functional hypotheses (http://genemania.org/; accessed November 19, 2018). A list of significant genes was uploaded to the GeneMania server. The network of genes is generated showing co-expression, physical interactions, co-localization, shared protein domains, predicted interactions, and genetic interactions. The created network highlights genes and scores them based on relative connections to the original list. These results may be used to prioritize gene candidates for future functional assays. The involved genes were reported as either over-or underexpressed in SUI patients versus continent woman.
The color of the line connecting the genes indicates the type of communication. Our diagram encompasses coexpression in purple lines, physical interactions in red lines, co-localization in blue lines, shared protein domains in yellowish lines, predicted communication in orange color, and genetic interactions in green lines. The genes depicted with an orange halo show significant genes found in our study. The remaining genes indicated by gray circles are related RT PCR: DCN mRNA was 3-fold higher in the case group in the proliferative phase (p > 0.05) and 8 times higher in the secretory phase (p = 0.02). FMOD mRNA was 2.5 times lower in the case group in the proliferative phase (p = 0.03) and no difference in the secretory phase. BGN showed no difference in both phases Western blot: BGN and DCN showed higher density in the case group in the secretory phase, while FMOD showed lower density in the case group in the secretory phase. No changes were detected in the proliferative phase GeneMania genes depending on their interaction with the lines (Fig. 2 ).
Results
The literature search returned 3109 studies. Of these studies, only four met the inclusion criteria for the review and were included in the final analysis. For the four included studies, we reported the SUI-related genes which were either over-or under-expressed in SUI patients versus continent woman. Gene expression was evaluated by using polymerase chain reaction (PCR) [14] [15] [16] [17] , microarray analysis [14, 16, 17] , immunohistochemistry [15] , immunofluorescence staining [15] , and Western blot [14] [15] [16] [17] .
The 184 genes were examined by the included studies ( Supplementary Table 1 ). A total of 11 genes were identified as being overexpressed in SUI patients [14] [15] [16] [17] , and a total of 2 genes were reported to be underexpressed [14, 14] . Of these 13 genes, growth factor receptor-bound protein 2 (GRB2) was reported to be over-expressed in 2 studies [14, 14] . A summary of reported outcomes of the included studies can be found in Table 1 .
GeneMANIA network analysis
We ran GeneMania to analyze the significantly over-(SKALP, COL17A1, PKP1, KRT16, DCN, BGN, BICD2, GRB2, STAT3, APOE, GOSR1) and under-expressed (FMOD, GBA) genes to further predict gene functions and network connections. Interactions between genes are displayed as a network diagram (Fig. 2) . The communication among the 13 genes was co-expressed interaction reported by the GeneMania data set. Elucidated genes were found to be involved in intermediate filament cytoskeleton organization and extracellular matrix organization ( Table 3) .
Upregulated genes SKALP (skin-derived antileukoproteinase)
Skin-derived antileukoproteinase (SKALP)/elafin is a wellknown, potent inhibitor of human leukocyte elastase and proteinase 3 [18] . Although SKALP is typically expressed in the presence of pathology, such as numerous skin cancers and inflammatory dermatoses, under normal conditions, SKALP is not expressed in the normal human epidermis [19] . SKALP also plays a substantial role in wound healing and elastin degradation [20] . Irregular epithelial differentiation and hyperproliferation have been linked to the existence of SKALP [21] . Chen et al. reported that elafin gene expression is associated with SUI. The upregulated elafin gene [14] .
Collagen type XVII alpha chain (COL17A1)
Collagen type XVII alpha chain (COL17A1) is a collagenous transmembrane protein [22] . Data suggest that robustness of the hemidesmosome complex in epithelium is associated with functional COL17A1 [23] . The presence of acquired COL17A1 mutations has been associated with junctional epidermolysis bullosa [24] . Reportedly, COL17A1 overexpression leads to extracellular matrix remodeling in pelvic tissue from women with SUI versus continent control subjects. Further investigation of altered expression of COL17A1 may have a role in the understanding of the genetic predisposition to SUI [14] .
Plakophilin 1 (PKP1)
Plakophilins (Pkp-1, −2, and − 3) are well-known armadillo repeat proteins linked to aggregation and sustainment of the dermasomal plaques in various tissues [25] . Skin fragility syndrome is associated with mutations in the plakophilin 1 gene [26] . Plakophilin 1 (PKP1), with its tumor suppressive role, is periodically downregulated in prostate cancer [27] . PKP1 has been identified as being over-expressed in patients with SUI compared with continent women. Comprehensive studies are needed to understand the role that overexpression of PKP1 plays in SUI pathogenesis [14] .
Keratin 16 (KRT16)
The epidermal barrier stress response is associated with the upregulation of keratin 16 [28] . Various mutations in the KRT6A, KRT6B, KRT6C, KRT16, and KRT17 are associated with pachyonychia congenita, which is a known cutaneous disorder [29] . Complex regional pain syndrome has also been associated with autoantibodies against KRT16 [30] . Upregulation of KRT16 gene has consistently been linked to SUI compared with controls, validated by numerous methods [14] .
Decorin (DCN)
Decorin (DCN) is one of the well-defined extracellular, small leucine-rich proteoglycans, existing in the extracellular matrix of vaginal wall tissue alongside collagen fibrils and elastin [31] . It also has anti-fibrotic, -inflammatory, and -cancer effects [32] . Decorin shares a common binding site for collagen I and binds to collagen I with great affinity [33] . It has been reported that DCN is required for perpetuating collagen fibril assembly and mechanical features of mature tendons. Reportedly, mRNA and protein expression of decorin has been confirmed by quantitative real-time PCR and performed Western blot analysis-a higher expression of DCN in tissues from women with SUI, leading to compromised function, by degradation of collagen and elastin fibers [15] .
Biglycan (BGN)
Biglycan (BGN) is abundantly expressed in the growing skeleton and skin surface of humans. Biglycan has been mapped to the Xq27-q28 region [34] . Multiple drug resistance has been correlated with upregulated expression of BGN via the NF-κB pathway in colon cancer [35] . A variety of human cancers are associated with impaired expression of BGN, which is a substantial member of the extracellular matrix [36] . Overexpression of BGN is also implicated in the development of SUI, since its overexpression is associated with SUI in women compared with continent controls [15] .
Protein bicaudal D homolog 2 (BICD2)
Bicaudal D2 (BICD2) is a cytoplasmic motor adaptor protein regulating the dynein-dynactin complex at various cellular mechanisms [37] . Juvenile amyotrophic lateral sclerosis is associated with mutated BICD2 [38] . Genetic studies have revealed that spinal muscular atrophy two is also linked to a interactions in green lines. The genes depicted with an orange halo show significant genes found in our study. The remaining genes indicated by gray circles are related GeneMania genes depending on their interaction with the lines [39] . Overexpressed BICD2 has been linked to the pathogenesis of SUI [16] .
Growth factor receptor-bound protein 2 (GRB2)
Growth factor receptor-bound protein 2 (GRB2) significantly contributes to vesicle trafficking by regulating signal mechanisms in neuronal tissue. It has an important role in an Alzheimer's disease-like conditions by handling toxic protein overload [40] . Its overexpression leads to apoptosis of nerve cells and the formation of neurofibrillary tangles. A report suggests that GRB2 has a substantial role in maintaining cytoskeletal assembly and provides insight for managing neurodegeneration [41] . GRB2 was over-expressed in two studies. Upregulated GRB2 is implicated in vaginal nerve degeneration in patients with SUI [14, 14] . Further investigation is needed to unravel the obscure functions of GRB2 in the pathogenesis of SUI.
Signal transducer and activator of transcription 3 (STAT3)
Signal transducer and activator of transcription-3 (STAT3) is a DNA-binding transcription factor, also known as acute phase response factor [42] . Inflammation in the lesion site following a spinal cord injury is implicated with signal transducer and activator of transcription 3 [43] . STAT3 is thought to play a key function by regulating reactive gliosis after spinal cord injury [44] . Liu et al. showed that upregulated STAT3 is linked to the pathogenesis of SUI [16] .
Apolipoprotein E (APOE)
Apolipoprotein E (APOE) is known for promoting neuronal repair and nerve regeneration. The lack of APOE has been implicated with diminished functional recovery after spinal cord injury [45] . Apolipoprotein E mainly functions in lipid and cholesterol metabolism [46] . Upregulated APOE gene expression and protein presence are implicated with nerve injury and the repair process in patients with SUI [17] . Reportedly, there is a contradiction between the apparent function for APOE and its upregulation in SUI patients.
Golgi SNAP receptor complex member 1 (GOSR1)
The Golgi SNAP receptor complex member 1 is represented as a membrane fusion between cargo-carrying vesicles and targeted membranes [47] . The Golgi SNAP receptor complex member 1 manifests intra-Golgi protein trafficking by possessing soluble NSF attachment protein receptor (SNARE) [48] . GOSR1 plays a crucial role in neurotransmitter transmission among the SNARE complex. Upregulated expression of GOSR1 was reported to exhibit a relation with patients with SUI [17] .
Down-expressed genes

Fibromodulin (FMOD)
Fibromodulin (FMOD) is a small, leucine-rich proteoglycan, abundantly produced by collagen-enriched tissues [49] . Fibromodulin plays a central role in the fibrillogenesis and is known for reducing scar formation in animal models [50] . FMOD gene expression was significantly lower in women with SUI compared with continent women [15] .
Glucocerebrosidase (GBA)
GBA encodes the lysosomal enzyme glucocerebrosidase (GCase), which is incorporated in sphingolipid metabolism.
GBA mutations are connected with the lysosomal storage disorder, Gaucher disease [51, 52] . Microarray analyses have demonstrated that the GBA gene was importantly downregulated in SUI tissue compared with asymptomatic controls [17] .
Discussion
This systematic review identified a total of 13 genes that potentially have significant involvement in the pathogenesis of SUI. The most significant genes were selected given the number of genes included in studies. Eleven genes were overexpressed [14] [15] [16] [17] , and two genes were underexpressed in women presenting with SUI [14, 14] . Of these genes, growth factor receptor-bound protein 2 (GRB2) was reported to be overexpressed in two studies [14, 14] . There are no overlapping genes, except GRB2, among the four studies.
GeneMANIA is a very flexible software used to explore and describe the linkage among the included genes using the genomics and proteomics data. GeneMANIA web application was utilized to explore the possible linked networks for the aforementioned genes via co-expression, physical interactions, co-localization, shared protein domains, functional assays, and genetic interactions (Fig. 2) . The most elucidated genes were found to be involved in intermediate filament cytoskeleton organization and extracellular matrix organization reported by GeneMANIA network analysis (Table 3 ). Further identification of significant genes' role in an extracellular matrix organization and intermediate filament cytoskeleton might lead to innovative diagnostic markers and novel molecular treatments in the urogynecologic applications.
Elafin, keratin 16, collagen type XVII, and plakophilin were constantly reported as increased ECM genes which play an important role in the remodeling of the pelvic floor supporting tissues [14] . DCN upregulation has been shown to substantially affect the development of SUI. DCN, BGN, and FMOD act as antifibrotic factors in the ECM by binding to TGF-b1, b2, and b3 [53] . Wen and colleagues reported lower concentrations of FMOD mRNA in the proliferative, but not in the secretory phase in the vaginal wall specimens from women with SUI. In the same report, higher concentrations of DCN mRNAwere found in the proliferative phase and more significantly in the secretory phase in SUI subjects. Also, they determined that DCN, BGN, and FMOD are linked with collagen type I and elastin in the vaginal wall tissue ECM [15] . GRB2, BICD2, and STAT3 levels were shown to be increased in the presence of SUI [16] . Growth factor receptorbound protein 2 and Golgi SNAP receptor complex member and glucosidase beta acid may play a neuro-degenerative role in SUI development [17] .
According to this review, APOE is upregulated in women with SUI [17] . APOE has a crucial role in modulating neuronal repair and protection after central nervous system repair. However, a lack of APOE is also found to have an association with decreased functional recovery in in-vitro studies [45] . Future studies are needed to reveal the underlying cause of this contradiction in SUI patients.
Furthermore, published data indicating that anomalous ECM genes including DCN, FMOD, and BGN are connected with SUI. Several animal and in-vitro studies have shown genetic alterations in these ECM genes. These findings reinforce the contribution of ECM genes to the occurrence of SUI. Genetic factors may predispose abnormal ECM, which is attenuated by trauma, hormonal environment, stress and differential mechanical stress loads on the injury site. Chronic abnormal remodeling with increased proteolytic activity presents in women with a genetic predisposing to SUI [54] . Taken together, exploring the underlying mechanism of alterations in ECM may be key to deciphering unknown principles and mechanisms contributing to or causing SUI.
Hypothetically, final protein formation from the gene transcription is direct [55] . Nevertheless, the occurrence of anomalous protein expression is not always considered a consequence of dysregulated gene expression. To overcome this limitation and to reduce bias, genes included in this review were only selected if evaluated by multiple analytical methods. The aforementioned genes were confirmed by several methods for quantification of gene expression. However, gene expression analysis in the current study does not represent a genome-wide expression profile, which is warranted to further confirm the genetic elements of SUI.
To our knowledge, this is the first systematic review to gather and highlight the genetic background of SUI. Overall, the quality of the included studies ranges from average to excellent. Limitations of the study could reside in the heterogeneity and the small number of the included studies. This might be due to the scarcity of published literature on this topic. Also, this might in part be due to the exclusion criteria, which were made to eliminate individual bias and prevent the inclusion of non-significant findings. Other limitations might include the small sample size in some of the included studies and the lack of information on the severity of SUI in the included patients.
To summarize, gene expression in women with clinical SUI compared with continent women has revealed several genes that might contribute to the development of SUI [14] [15] [16] [17] . Potential gene set candidate functional pathways are probably involved in intermediate filament cytoskeleton and extracellular matrix organization. Comprehensive experiments and wide-genome analyses should be conducted to further study and confirm the differential expressions on these genes. The outcomes of this systematic review may be laying the groundwork for the development of future targeted therapies and novel biomarker detection for the treatment, early detection, and possible prediction and prevention of future development of SUI. 
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